Flomoxef

Flomoxef

Clinical data
Trade names	Flumarin
AHFS/Drugs.com	International Drug Names
ATC code	J01DC14 (WHO)
Identifiers
IUPAC name (6R,7R)-7-[[2-(Difluoromethylsulfanyl)acetyl]amino]-3-[[1-(2-hydroxyethyl)tetrazol-5-yl]sulfanylmethyl]-7-methoxy-8-oxo-5-oxa-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
JSmol)	Interactive image
Melting point	82.5 to 87.5 °C (180.5 to 189.5 °F)
SMILES CO[C@@]1([C@@H]2N(C1=O)C(=C(CO2)CSc3nnnn3CCO)C(=O)O)NC(=O)CSC(F)F
InChI InChI=1S/C15H18F2N6O7S2/c1-29-15(18-8(25)6-31-13(16)17)11(28)23-9(10(26)27)7(4-30-12(15)23)5-32-14-19-20-21-22(14)2-3-24/h12-13,24H,2-6H2,1H3,(H,18,25)(H,26,27)/t12-,15+/m1/s1 N Key:UHRBTBZOWWGKMK-DOMZBBRYSA-N N
NY (what is this?)  (verify)

Flomoxef is an oxacephem antibiotic that was developed by Shionogi.

It has been classified either as a second-generation ^[1] or fourth-generation cephalosporin.^[2]

It was patented in 1982 and approved for medical use in 1988 under the trade name Flumarin.^[3]

This systemic antibiotic-related article is a stub. You can help Wikipedia by expanding it.

• v
• t
• e